John Simard - 31 Dec 2024 SCHEDULE 13G/A Report for XBIOTECH INC. Common Shares, no par value (XBIT)

Ownership signal CIK-linked ownership evidence from parsed SEC filings. 2 signals
Large-stake signal

Form

SCHEDULE 13G/A

Passive or exempt beneficial ownership filing.

Ownership

20%

Beneficial ownership of this reported class.

Shares

6,624,530 shares

Shares beneficially owned as disclosed.

Event date

31 Dec 2024

Date tied to the ownership event or amendment.

Accepted by SEC

27 Jan 2025

EDGAR acceptance date.

How to read this large-stake filing
  • Schedule 13D/G filings focus on beneficial ownership stakes, not a full portfolio.
  • Compare this filing with the holder history and issuer page before treating the percentage as a current position.
  • Use amendments to understand whether the disclosed stake increased, decreased, or changed reporting status.
Subject security Names, identifiers, and filing context for this profile. 2 source fields
Symbol
XBIT
Shares outstanding
33,289,095 shares
Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
SCHEDULE 13G/A
Accepted by SEC
27 Jan 2025, 14:36:21 UTC
Event date
31 Dec 2024
Next SEC filing
23 Jan 2026
Source filing
View source filing

Key filing fact

John Simard disclosed 20% ownership in XBIOTECH INC. Common Shares, no par value (XBIT) on 31 Dec 2024.

Key facts

  • John Simard filed SCHEDULE 13G/A for XBIOTECH INC. Common Shares, no par value (XBIT).
  • Disclosed ownership: 20%.
  • Date of event: 31 Dec 2024.

Change

  • No earlier schedule filing is available for direct comparison.
  • Current filing was accepted on 27 Jan 2025, 14:36.

Research use

  • This page turns one Schedule 13D/G filing into a quick large-stake read before the raw reporting-person rows.
  • Use the linked SEC filing as the source of truth for ownership percentages, shares, and reporting-party details.

Evidence

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

View source filing

Reporting persons

Disclosed reporting parties (1)

Names, ownership percentages, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.

Name Ownership Shares owned Sole voting power Shared voting power Signature Title CIK
John Simard 20% 6,624,530 6,624,530 0 /s/ John Simard John Simard/President & CEO, XBiotech Inc.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .